B+
Bull case
20%
Probability
Target price
$63.00
Analysis reference price unavailable
Analysis 2026-02-04 · RankAlpha Sentiment AI
SRRK
Scholar RockDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$50.34
Analysis reference price unavailable
Analysis 2026-02-04 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-02-04 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-04
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.8
Score
AI commentary
Analyst coverage skews constructive with a median target above the current anchor and several recent upward revisions cited [#SERP-2], [#SERP-7]. Coverage dispersion (low-to-high spread) implies event-driven volatility around clinical and partnership catalysts [#SERP-3].
RankAlpha Sentiment AI - 2026-02-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05catalystQuarterly results / corporate updateHigh impact
Quarterly results and management commentary that typically move small-/mid-cap biotech shares; analysts will watch guidance and cash runway [#SERP-2].
2026-05-05catalystAnalyst coverage updates / price-target revisionsHigh impact
Broker notes and target changes (recent upgrade activity noted) can shift sentiment and flows quickly [#SERP-7].
2026-12-31eventPotential lead-program clinical readout (assumed window)High impact
Binary efficacy/safety readout could materially re-rate the stock; expected_date is an assumed window end due to no public schedule [#SERP-1].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-04 • Updated nightlySource: Internal modelMethodology